Financiado en parte por Danone
Effect of increased water intake on plasma copeptin in patients with chronic kidney disease: results from a pilot randomised controlled trial
Sontrop JM, Huang SH, Garg AX, Moist L, House AA, Gallo K, Clark WF
BMJ open · 29 citas
Etiquetas de revisión
Financiado por la industriaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiado por la industria
- Empresa
- Danone
Según 1 financiador declarado.
Publicación
- Publicado
- 2015-11-01 · BMJ Open · vol. 5 · número 11 · pág. e008634
- Editorial
- BMJ
- Citado
- 39 citas · más que el 96% de estudios similares · 5.1× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 56 trabajos
- Acceso
- Acceso abierto (revista) · CC-BY-NC
- Áreas de investigación
- Electrolyte and hormonal disorders · Ion Transport and Channel Regulation · Sodium Intake and Health
- Palabras clave
- Copeptin, Medicine, Kidney disease, Vasopressin, Internal medicine, Renal function, Urine, Urinalysis, Randomized controlled trial, Endocrinology, Urine osmolality, Gastroenterology
- MeSH
- kidney, humans, glycopeptides, glomerular filtration rate, drinking, aged, middle aged, canada, female, male, renal insufficiency, chronic, biomarkers
7 autores
- Jessica M. Sontrop🇨🇦Western University; London Health Sciences Centre
- Shi-Han Huang🇨🇦London Health Sciences Centre
- Amit X. Garg🇨🇦Western University; London Health Sciences Centre
- Louise M. MOIST🇨🇦Western University; London Health Sciences Centre
- Andrew A. House🇨🇦London Health Sciences Centre
- Kerri Gallo🇨🇦London Health Sciences Centre
- William F. Clark🇨🇦 · autor de correspondenciaLondon Health Sciences Centre
Resumen
El texto original del estudio, en el idioma en que se publicó.
Objectives
Increased water intake may have a beneficial effect on the kidney through suppression of plasma vasopressin. We examined the effect of increased water intake on plasma copeptin (a marker of vasopressin) over 6 weeks in patients with chronic kidney disease.
Design
Secondary analysis of a randomised controlled parallel-group pilot trial.
Setting
Canada, 2012-2013.
Participants
28 patients with stage 3 chronic kidney disease randomised (2:1) to a hydration (n=17) or control group (n=11).
Intervention
The hydration group was coached to increase water intake by up to 1.5 L/day for 6 weeks. The control group was asked to maintain regular water intake.
Measures and outcomes
Participants provided blood and 24 h urine samples at baseline and 6 weeks. Change in plasma copeptin was compared within and between study groups.
Results
Participants were 64% male with a mean age of 62 years and an estimated glomerular filtration rate of 40 mL/min/1.73 m(2). Between baseline and 6 weeks, 24 h urine volume increased by 0.7 L/day in the hydration group, rising from 2.3 to 3.0 L/day (p=0.01), while decreasing by 0.3 L/day among controls, from 2.0 to 1.7 L/day (p=0.07); between-group difference: 0.9 L/day (95% CI 0.37 to 1.46; p=0.002). In the hydration group, median copeptin decreased by 3.6 pmol/L, from 15.0 to 10.8 pmol/L (p=0.005), while remaining stable among controls at 19 pmol/L (p=0.76; p=0.19 for the between-group difference in median change); the between-group difference in mean change was 5.4 pmol/L (95% CI -1.2 to 12.0; p=0.11).
Conclusions
Adults with stage 3 chronic kidney disease can be successfully randomised to drink approximately 1 L more per day than controls. This increased water intake caused a significant decrease in plasma copeptin concentration. Our larger 12-month trial will examine whether increased water intake can slow renal decline in patients with chronic kidney disease.
Trial registration number
NCT01753466.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY-NC).
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.